Type of Article:  Short Communication

Volume 8; Issue 2 (April 2020)

Page No.: 3438-3442

DOI: https://dx.doi.org/10.16965/ijpr.2020.126


R. Vinodh Rajkumar.

Physiotherapist & Anthropologist, Director – Prabhanjeet Fitness Research Institute OPC Private Limited, Bangalore, Karnataka, India. E-Mail: dreamofkalam@rediffmail.com


Human existence and their health rely on their intellectual interactions with ecosystem which eventually accompanies brilliant technological innovations. At par with the technological progress, humans also have been facing several intimidating communicable and non-communicable diseases. Amidst such disease threats, humans have discovered multiple ways to uplift the average life span all over the globe but still not up to the fitness benchmarks of healthy ageing trajectory. COVID-19 has specifically revealed the fragility of humans as they continue succumbing exponentially to the interactions of this communicable disease with their existing non-communicable diseases like hypertension, cardiac pathology and diabetes. In human evolution, the COVID-19 pandemic could be the most perfect synapse or intersection of non-communicable diseases with this transmissible disease leading to a situation that can be even named as “Global Medical Stampede” characterized by sudden increase in the number of patients requiring life-saving procedures for which there is lack of adequate manpower and technological support in health care system. This whole chaotic scenario could easily trigger acute psychological and physiological stress primarily caused by fear among the public favoring the frightening consequences of the pandemic. This article aims to suggest refinement in public health paradigms to enable preparations to face such disease threats from the immediate future without further procrastination.

Key words: COVID-19, Pandemic, Epidemiological Transition, Public Health, Compression of Morbidity, Polypharmacy, Pharmacogenomics, Co-morbidities, Somatotype, Healthy ageing.


  1. Continuing Medical Education, Anthropometry to improve public health. Indian Journal of Community Medicine. 1993; 18 (4): 166-167.
  2. Bhavani Shankar. Trivialization of Health Care Scenario in Rural India: A Sociological Concern. International Journal of Humanities & Social Science Studies (IJHSSS), 2016; 2 (6) : 89-97.
  3. Vinodh Rajkumar. Gravitational Torque Deficiency Syndrome – a prospective clinical terminology- part 1, Int J Physiother Res 2016, Vol 4(5):1668-78.
  4. Evans WJ, Campbell WW. Sarcopenia and age-related changes in body composition and functional capacity. J Nutr. 1993 Feb;123(2 Suppl):465-8.
  5. Gruenberg EM. The failures of success. 1977. Milbank Q. 2005;83(4):779–800.
  6. Fries JF, Bruce B, Chakravarty E. Compression of morbidity 1980-2011: a focused review of paradigms and progress. J Aging Res. 2011.
  7. Vinodh Rajkumar. Endomorphy dominance among non-athlete population in all the ranges of body mass index. International Journal of Physiotherapy and Research. 2015;3 (3):1068-1074.
  8. Last JM, editor. A dictionary of epidemiology, 4th edition. New York: Oxford University Press; 2001.
  9. H.Wahdan, The Epidemiological Transition, Eastern Mediterranean Health Journal. 1996; Vol.2, No.1.
  10. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020; Mar 12. pii: S1201-9712(20)30136-3. doi: 10.1016/j.ijid.2020.03.017. [Epub ahead of print]
  11. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tobacco Induced Diseases. 2020;18(March):20. doi:10.18332/tid/119324.
  12. Kurt Riezler, The Social Psychology of Fear. American Journal of Sociology. 1944; 49, No. 6, pp. 489-498.
  13. Weiss MG, Ramakrishna J. Stigma interventions and research for international health. Stigma and Global Health: Developing a Research Agenda; 2001. September 5–7; Bethesda, Maryland. [cited 2003 Aug 1].
  14. Das V. Stigma, contagion, defect: issues in the anthropology of public health. Stigma and Global Health: Developing a Research Agenda; 2001. September 5–7; Bethesda, Maryland. [cited 2003 Aug 8].
  15. Person B, Sy F, Holton K, Govert B, Liang A; National Center for Infectious Diseases/SARS Community Outreach Team. Fear and stigma: the epidemic within the SARS outbreak. Emerg Infect Dis. 2004;10(2):358–363. doi:10.3201/eid1002.030750
  16. Goldstein DS. Stress-induced activation of the sympathetic nervous system. Baillieres Clin Endocrinol Metab. 1987;1(2):253-78.
  17. Yaribeygi H, Panahi Y, Sahraei H, Johnston TP, Sahebkar A. The impact of stress on body function: A review. EXCLI J. 2017; 16:1057–1072. Published 2017 Jul 21. doi:10.17179/excli2017-480.
  18. Pike BL, Saylors KE, Fair JN, et al. The origin and prevention of pandemics. Clin Infect Dis. 2010;50(12):1636–1640. doi:10.1086/652860
  19. (Yi-Chi Wua, Ching-Sung Chena, Yu-Jiun Chan. The outbreak of COVID-19: An overview. J Chin Med Assoc. (2020) 83: 217-220).
  20. Munster VJ, Koopmans M, Doremalen NV, Riel DV, Wit ED. A novel coronavirus emerging in China – Key Questions for Impact Assessment. N Engl J Med 2020. DOI: 10.1056/NEJMp2000929.
  21. Pengfei Sun, Xiaosheng Lu, Chao Xu, Wenjuan Sun, Bo Pan. Understanding of COVID‐19 based on current evidence. J Med Virol. 2020;1-4.
  22. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020 Mar 11 [Online ahead of print]
  23. Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivelä SL, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol. 2002 Aug;55(8):809-17.
  24. Golchin N, Frank SH, Vince A, Isham L, Meropol SB. Polypharmacy in the elderly. J Res Pharm Pract. 2015;4(2):85–88. doi:10.4103/2279-042X.155755.
  25. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014 Jan;13(1):57-65. doi: 10.1517/14740338.2013.827660. Epub 2013 Sep 27.
  26. Zhou ZW,Chen XW, Sneed KB, Yang YX, Zhang X, He ZX, Chow K, Yang T, Duan W, Zhou SF. Clinical association between pharmacogenomics and adverse drug reactions. Drugs. 2015 Apr;75(6):589-631. doi: 10.1007/s40265-015-0375-0.
  27. Roses AD. Pharmacogenetics and the practice of medicine. Nature. 2000 Jun 15;405(6788):857-65.
  28. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350. doi:10.1038/nature15817.
  29. Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol. 2019 May;12(5):407-442. doi: 10.1080/17512433.2019.1597706. Epub 2019 Apr 24.
  30. Cascorbi I, Schwab M. Epigenetics in Drug Response. Clin Pharmacol Ther. 2016 May;99(5):468-70. doi: 10.1002/cpt.349.
  31. Tan and J. Aboulhosn, The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. International Journal of Cardiology, https://doi.org/10.1016/j.ijcard.2020.03.063
  32. Diastolic blood pressure or actually it is baseline systolic blood pressure? R.Vinodh Rajkumar. Int J Physiother Res 2015;3(4):1126-1132.
  33. Michelle A Cretikos, Rinaldo Bellomo, Ken Hillman, Jack Chen, Simon Finfer, Arthas Flabouris. Respiratory rate: the neglected vital sign. Med J Aust. 2008; 188 (11):657 – 659.
  34. https://www.researchgate.net/post/Who_first_discovered_120_80_mmHg_as_normal_BP_What_was_the_basis_to_define_120_80_mmHg_as_normal_BP
  35. Hickey T, Dean K, Holstein BE. Emerging trends in gerontology and geriatrics: implications for the self-care of the elderly. Soc Sci Med. 1986;23(12):1363-9.

Cite this article: R. Vinodh Rajkumar. EPIDEMIOLOGICAL INTERSECTION: THE REVELATION OF COVID – 19 PANDEMIC. Int J Physiother Res 2020;8(2):3438-3442. DOI: 10.16965/ijpr.2020.126